How is molecular profiling reshaping HR+ metastatic breast cancer treatment?

In this episode of CHM Conversations, Dr. Erica Mayer and Dr. Seth Wander navigate the evolving landscape of endocrine resistance and the PI3K/AKT pathway. They discuss the shifting roles of ESR1 and PIK3CA mutations, the rise of ctDNA in clinical sequencing, and the practicalities of integrating newer therapies like capivasertib.

From proactive toxicity monitoring to the future of combination care, this discussion explores the next era of precision medicine in HR+ breast cancer.

An essential resource for clinicians navigating the future of endocrine therapy and targeted treatment strategies.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #HRPositive #Oncology #PIK3CA #ESR1 #ctDNA #Capivasertib #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Can early intervention change the course of metastatic HR+ breast cancer?

In this expert discussion, Dr. Seth Wander and Dr. Erica Mayer break down the practice-changing SERENA-6 trial and the emerging role of camizestrant in ESR1-mutated metastatic breast cancer.

From ctDNA monitoring and early resistance detection, to quality-of-life improvements and precision endocrine therapy—they explore how oral SERDs may redefine treatment sequencing in HR-positive, HER2-negative disease.

Topics include:

• SERENA-6 trial design and results

• ESR1 mutations and endocrine resistance

• ctDNA-guided treatment decisions

• Quality-of-life outcomes with camizestrant

• Oral SERDs vs aromatase inhibitors

• The future of precision endocrine therapy

🎧 Watch now on Community Health Media.

#BreastCancer #HRPositive #ESR1 #Camizestrant #SERENA6 #Oncology #BreastOncology #PrecisionOncology #ctDNA #OralSERD #MetastaticBreastCancer #CancerResearch #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

In this special Spanish-language episode, experts Dr. Ricardo Alvarez, Dr. Marcela Mazo-Canola, and Dr. Ana Sandoval-Leon sit down to discuss the breakthroughs transforming modern breast oncology.

The panel explores how personalized medicine is redefining outcomes and quality of life across the spectrum of HER2-positive, triple-negative, and hormone receptor-positive breast cancers. From the integration of genomic testing and liquid biopsies to the rise of antibody-drug conjugates (ADCs), this discussion covers the frontline of clinical practice.

Topics include:

• Advances in HER2+ and triple-negative breast cancer

• Genomic testing and liquid biopsy

• ADCs and targeted therapies

• CDK4/6 inhibitors and PARP inhibitors

• Immunotherapy and emerging treatment strategies

• Clinical trials and access to care in Latin America

• Toxicity management and quality of life

• The future of personalized breast cancer treatment

An essential conversation for oncologists, healthcare professionals, and patients interested in the future of breast cancer care — presented entirely in Spanish.

▶️ Subscribe for more expert oncology conversations.

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

What happens when breast and thoracic oncology collide over the future of ADCs?

In this cross-specialty conversation, Dr. Jason Mouabbi and Dr. Eric Singhi explore how antibody-drug conjugates are reshaping both breast and lung cancer treatment. From T-DXd and datopotamab deruxtecan to HER2-low disease, EGFR-mutated NSCLC, ILD management, sequencing strategies, and the future of combination ADC therapy — this episode dives deep into the rapidly evolving world of precision oncology.

They discuss:

• Why ADCs are transforming metastatic care

• Managing ILD, stomatitis, ocular toxicity, and nausea

• Sequencing ADCs and resistance mechanisms

• Combining ADCs with immunotherapy and targeted therapy

• HER2-low, ultra-low, and biomarker-driven treatment strategies

• How breast and lung oncology are learning from each other

🎧 A must-watch conversation on the next era of targeted cancer therapy.

#BreastCancer #LungCancer #ADCs #TDXd #DatopotamabDeruxtecan #HER2Low #EGFR #PrecisionOncology #ThoracicOncology #MedicalOncology #CancerResearch #OncologyPodcast #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

What if we could detect endocrine resistance before it shows up on scans?

In this CHM Conversations episode, Dr. Sigrun Hallmeyer and Dr. William Gradishar break down the SERENA-6 trial and what it means for the future of HR-positive, HER2-negative metastatic breast cancer.

From early detection of ESR1 mutations using ctDNA to switching therapy before clinical progression, this discussion explores how molecular monitoring is reshaping treatment decisions, extending progression-free survival, and preserving quality of life.

The conversation also dives into real-world implementation, patient experience, cost considerations, and what comes next as oncology moves toward more personalized, biology-driven care.

A must-watch for clinicians navigating the evolving endocrine landscape.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #HRPositive #Oncology #ESR1 #ctDNA #SERENA6 #EndocrineTherapy #MedicalOncology #PrecisionOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

The HER2-positive landscape is undergoing its most significant shift in over a decade!

In this in-depth CHM Conversations episode, VK Gadi and Tarah Ballinger break down the practice-changing data behind DB09, PATINA, HER2CLIMB-05, DB05, and DB11 — and what these trials mean for real-world patient care.

This deep dive explores the critical transition from traditional maintenance habits to optimized ADC persistence—balancing unprecedented efficacy with rigorous safety standards and ILD monitoring. From the potential for durable responses in metastatic disease to the expanding role of ADCs in early-stage neoadjuvant and adjuvant settings, this discussion provides a comprehensive roadmap for the entire patient journey.

A must-watch conversation for oncologists, researchers, and anyone following the next era of HER2-directed therapy.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #HER2Positive #TDXd #DESTINYBreast09 #Oncology #MedicalOncology #CancerResearch #PrecisionOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

In this expert discussion, Dr. VK Gadi and Dr. Ruta Rao break down the data that’s reshaping treatment for HER2-positive breast cancer — from DESTINY-Breast 05 and 11 to the first-line metastatic implications of DESTINY-Breast 09.

They explore what the numbers really mean for patients with residual disease, how CNS risk and toxicity factor into decision-making, and where T-DXd may (or may not) replace existing standards of care.

A candid, data-driven conversation for clinicians navigating HER2+ treatment today — and preparing for what comes next.

#HER2Positive #BreastCancer #TDXd #Oncology #CancerResearch #ESMO #ASCO #MedicalOncology #PrecisionMedicine #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for first-line treatment of metastatic HER2-positive breast cancer.

From challenging the long-standing THP standard to unpacking unprecedented progression-free survival, higher complete response rates, and CNS activity with T-DXd, this discussion explores how and why first-line decision-making is evolving. The panel also dives into patient selection, toxicity management, ILD monitoring, dose optimization, induction vs maintenance strategies, and how to frame these advances in real-world patient conversations.

A must-watch for clinicians navigating the next era of HER2-positive metastatic breast cancer care.

#HER2Positive #BreastCancer #DESTINYBreast09 #TDXd #Oncology #MedicalOncology #BreastOncology #CancerResearch #ClinicalTrials #PrecisionOncology #ESMO #ASCO #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded with Drs. Neil Iyengar and Komal Jhaveri, this in-depth discussion breaks down the most practice-shifting data in early-stage HER2-positive breast cancer — from neoadjuvant to adjuvant decision-making.

The conversation explores DESTINY-Breast11 and its unprecedented pathologic complete response rates with sequential T-DXd followed by THP, including an 83% pCR in hormone receptor–negative disease. The panel also examines safety, ILD risk, anthracycline-free strategies, and how these results may reshape neoadjuvant standards.

The discussion then moves to DESTINY-Breast05, where T-DXd demonstrated superiority over T-DM1 in the residual disease setting, with a hazard ratio of 0.5 for invasive disease-free survival — raising critical questions about patient selection, CNS recurrence, and curative intent strategies.

A must-watch episode for clinicians navigating the rapidly evolving HER2-positive landscape.

#BreastCancer #HER2Positive #EarlyStageBreastCancer #Oncology #MedicalOncology #DESTINYBreast11 #DESTINYBreast05 #TDXd #AntibodyDrugConjugates #NeoadjuvantTherapy #AdjuvantTherapy #CancerResearch #ClinicalTrials #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded live with Drs. Gregory Vidal and Nusayba Bagegni, this in-depth conversation tackles one of the most provocative questions in HER2-positive metastatic breast cancer today: are we finally approaching cure?

The discussion spans more than a decade of progress — from the CLEOPATRA regimen and its long tail of durable responders to the practice-changing data from DESTINY-Breast09 showing a 40-month progression-free survival with T-DXd plus pertuzumab.

The panel explores how Patina, HER2CLIMB-05, endocrine therapy integration, CNS disease, and patient-specific risk factors are reshaping first-line decision-making. With more options than ever before, this episode highlights why precision, sequencing, and shared decision-making now define HER2-positive care.

#BreastCancer #HER2Positive #MetastaticBreastCancer #Oncology #MedicalOncology #DESTINYBreast09 #PatinaTrial #HER2CLIMB #TDXd #AntibodyDrugConjugates #PrecisionOncology #CancerResearch #ClinicalTrials #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media